The Proteasome: More Than a Means to an End.

Structure

Department of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada. Electronic address:

Published: August 2016

The proteasome regulates timed degradation of proteins using both intrinsic and extrinsic receptors that recognize polyubiquitin chains on targets. In this issue of Structure, Chen et al. (2016) outline the structural basis of how intrinsic receptors prefer ubiquitin-like domains rather than ubiquitin, to bind extrinsic co-receptors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.str.2016.07.005DOI Listing

Publication Analysis

Top Keywords

proteasome proteasome
4
proteasome regulates
4
regulates timed
4
timed degradation
4
degradation proteins
4
proteins intrinsic
4
intrinsic extrinsic
4
extrinsic receptors
4
receptors that recognize
4
that recognize polyubiquitin
4

Similar Publications

Activation of the 26S Proteasome to Reduce Proteotoxic Stress and Improve the Efficacy of PROTACs.

ACS Pharmacol Transl Sci

January 2025

Department of Genetics and Microbiology, Charles University and Research Center BIOCEV, Pru°myslová 595, Vestec 252 50, Czech Republic.

The 26S proteasome degrades the majority of cellular proteins and affects all aspects of cellular life. Therefore, the 26S proteasome abundance, proper assembly, and activity in different life contexts need to be precisely controlled. Impaired proteasome activity is considered a causative factor in several serious disorders.

View Article and Find Full Text PDF

A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment.

Theranostics

January 2025

Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.

Proteolysis Targeting Chimeras (PROTACs) are bifunctional compounds that have been extensively studied for their role in targeted protein degradation (TPD). The capacity to degrade validated or undruggable targets provides PROTACs with significant potency in cancer therapy. However, the clinical application of PROTACs is limited by their poor potency and unfavorable pharmacokinetic properties.

View Article and Find Full Text PDF

HUVECs-derived exosomes increase neovascularization and decrease limb necrosis in hindlimb ischemia.

Narra J

December 2024

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Chronic limb-threatening ischemia (CLTI) is the most severe manifestation of peripheral arterial disease (PAD) and imposes a significantly high burden due to its high risk of mortality and amputation. Revascularization is the first-line treatment for CLTI; however, the amputation rate remains high, and approximately one-third of patients are not eligible for this treatment. Therefore, there is an urgent need for more effective therapeutic strategies.

View Article and Find Full Text PDF

Proteolysis-targeting influenza vaccine strains induce broad-spectrum immunity and in vivo protection.

Nat Microbiol

January 2025

State key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.

Generating effective live vaccines from intact viruses remains challenging owing to considerations of safety and immunogenicity. Approaches that can be applied in a systematic manner are needed. Here we created a library of live attenuated influenza vaccines by using diverse cellular E3 ubiquitin ligases to generate proteolysis-targeting (PROTAR) influenza A viruses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!